Tizanidne Hydrochloride Capsule
Product Images NDC 72162-1860

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 72162-1860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621860)

Label for Tizanidine Hydrochloride Capsules, 2 mg strength, containing 150 capsules. The product is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Alkem Laboratories Ltd. The label includes storage instructions, a caution about child-resistant packaging, and a notice that the product is not interchangeable with tizanidine tablets or Zanaflex® tablets. The NDC number 72162-1860-2 is also displayed.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of tizanidine hydrochloride, showing its molecular arrangement with chlorine, nitrogen, sulfur atoms, and hydrochloride component.*

FDA Label Image

Tiz02 (Tiz02)

A pharmacokinetic graph showing plasma tizanidine concentration (ng/mL) over time (hours from dosing) for 2 mg and 4 mg doses of tizanidine tablets and capsules, with and without food. The plot displays multiple data series comparing these conditions up to 24 hours post-dose.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing improvement in Ashworth Score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph illustrates changes in score from 0 to 6 hours post-dose, with 16 mg showing the greatest improvement, followed by 8 mg, and placebo showing minimal change.*

FDA Label Image

Tiz04 (Tiz04)

A line chart showing improvement in Ashworth Score over time with three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). It compares tizanidine (mean dose 28.8 mg) represented with squares and placebo represented with circles, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.